AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37706671 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR training
Number of subjects: 28
Study 37706671 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR training
Number of subjects: 28
Study 37706686 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically informed video series
Number of subjects: 0
Study 37706686 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37707290 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO measurements
Number of subjects: 49
Study 37707316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37707361 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Component Strengths-Building Intervention
Number of subjects: 0
Study 37707361 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 0
Study 37707375 — intervention group
Group type: EXPERIMENTAL
Intervention: SRC regions
Number of subjects: 20
Study 37707401 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) 50%
Number of subjects: 20
Study 37707401 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) 75%
Number of subjects: 20
Study 37707401 — intervention group
Group type: COMPARATOR
Intervention: Non-Deep Learning (non-DL)
Number of subjects: 20
Study 37707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at Home-Parents (SAHP) intervention; delivered using synchronous video technology
Number of subjects: 0
Study 37707478 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (14-week supervised cardiovascular, resistance, and flexibility training, 2 group and 1 individual session per week)
Number of subjects: 58
Study 37707478 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (14-week supervised cardiovascular, resistance, and flexibility training)
Number of subjects: 58
Study 37707506 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (RT) at 60-70Gy in 2 Gy fractions
Number of subjects: 49
Study 37707506 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (RT)
Number of subjects: 49
Study 37707508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance inspiratory muscle strength training (IMST)
Number of subjects: 35
Study 37707508 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 35
Study 37707673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan subcutaneous self-administration (twice or three times weekly or every 3 days) for an additional 48 weeks
Number of subjects: 64
Study 37707673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan subcutaneous self-administration
Number of subjects: 64
Study 37707701 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar liraglutide (Melitide)
Number of subjects: 300
Study 37707701 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 37707764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg
Number of subjects: 0
Study 37707764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 0
Study 37707764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37707791 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab (anti-PD-L1) monotherapy
Number of subjects: 83
Study 37707791 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus oleclumab (anti-CD73)
Number of subjects: 83
Study 37707791 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus monalizumab (anti-NKG2A)
Number of subjects: 83
Study 37707791 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide)
Number of subjects: 83
Study 37707811 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone without breast surgery
Number of subjects: 31
Study 37707817 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent influenza vaccine
Number of subjects: 3094
Study 37707817 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 3094
Study 37707817 — intervention group
Group type: EXPERIMENTAL
Intervention: ILI activity increase by 1%
Number of subjects: 3094
Study 37707820 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized stereotactic ablative radiotherapy (SABR) with doses ranging from 25 Gy in 1 fraction for peripheral tumors (0-10 cm3) to 60 Gy in 8 fractions for central tumors (>30 cm3).
Number of subjects: 217
Study 37707820 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized stereotactic ablative radiotherapy (SABR)
Number of subjects: 217
Study 37707822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting individualized pretest counseling and posttest counseling for those without pathogenic variants during remote genetic testing.
Number of subjects: 3839
Study 37707822 — intervention group
Group type: COMPARATOR
Intervention: Control arm with pretest and/or posttest genetic counseling.
Number of subjects: 3839
Study 37707942 — intervention group
Group type: COMPARATOR
Intervention: Control arm received daily walk step reminders to walk at least 5000 steps per day
Number of subjects: 41
Study 37707944 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy (iCBT) with Virtual Reality Exposure Therapy (VRET) - 14-week program including 9 web-based modules and 5 individual counseling sessions (2 VRET sessions)
Number of subjects: 329
Study 37707944 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC) group
Number of subjects: 329
Study 37707948 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention (JITAI) with 5-6 messages per week
Number of subjects: 36
Study 37707948 — intervention group
Group type: COMPARATOR
Intervention: No messages from the mobile app
Number of subjects: 36
Study 37707956 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles (EVs) from patients with heart failure and cardiorenal syndrome (HF-CRS)
Number of subjects: 0
Study 37707956 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-RNAs from HF-CRS patients
Number of subjects: 0
Study 37707956 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors and mimics of miRNAs
Number of subjects: 0
Study 37707956 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma EVs from patients with CRS
Number of subjects: 0
Study 37708435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health application designed to increase AUD treatment engagement
Number of subjects: 60
Study 37708435 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 60
Study 37708502 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine education plus video education (intervention)
Number of subjects: 200
Study 37708502 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge education (control)
Number of subjects: 200
Study 37708528 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (17-g dose by mouth on postoperative day 1)
Number of subjects: 2
Study 37708528 — intervention group
Group type: COMPARATOR
Intervention: Docusate sodium (100 mg starting the day of surgery and continued twice daily at home)
Number of subjects: 2
Study 37708528 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 2
Study 37708528 — intervention group
Group type: COMPARATOR
Intervention: Docusate sodium
Number of subjects: 2
Study 37708629 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen-deprivation therapy (ADT)
Number of subjects: 1052
Study 37708629 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 1052
Study 37708629 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1052
Study 37708699 — intervention group
Group type: EXPERIMENTAL
Intervention: MC1R risk information (average, higher)
Number of subjects: 463
Study 37708904 — intervention group
Group type: EXPERIMENTAL
Intervention: NALIRIFOX
Number of subjects: 770
Study 37708904 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel and gemcitabine
Number of subjects: 770
Study 37708911 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab + lenalidomide + bortezomib + dexamethasone)
Number of subjects: 207
Study 37708911 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd
Number of subjects: 207
Study 37708911 — intervention group
Group type: COMPARATOR
Intervention: RVd
Number of subjects: 207
Study 37708912 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus HIPEC (100 mg/m²)
Number of subjects: 245
Study 37708912 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 245
Study 37709198 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial labor analgesia (NLA)
Number of subjects: 1885
Study 37709198 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative approaches for labor analgesia
Number of subjects: 1885
Study 37709198 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1885
Study 37709198 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery in level I units
Number of subjects: 1885
Study 37709198 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial labor analgesia (NLA) during CD
Number of subjects: 1885
Study 37709198 — intervention group
Group type: COMPARATOR
Intervention: NLA vs no NLA
Number of subjects: 1885
Study 37709198 — intervention group
Group type: COMPARATOR
Intervention: Scheduled vs non-scheduled CD
Number of subjects: 1885
Study 37709280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg + placebo (DX1)
Number of subjects: 434
Study 37709280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg + dexamethasone 24 mg (DX2)
Number of subjects: 434
Study 37709280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 37709304 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes identification using fasting glucose, HbA1c, OGTT results, or history of pre-existing diabetes.
Number of subjects: 11700
Study 37709304 — intervention group
Group type: COMPARATOR
Intervention: Repeat tests for individuals identified with diabetes and a random selection of controls.
Number of subjects: 11700
Study 37709304 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for 1 year after enrollment.
Number of subjects: 11700
Study 37709305 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT for informal caregiver (ACT-IC) intervention delivered over a 9-week period consisting of a collaborative goal-setting session, nine online ACT modules, nine telephone-based motivational coaching sessions and 6 monthly booster sessions following the main intervention period.
Number of subjects: 30
Study 37709305 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT for informal caregiver (ACT-IC) intervention
Number of subjects: 30
Study 37709311 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of oral vancomycin every 6 hours for 10 days
Number of subjects: 104
Study 37709311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 37709314 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT + immunotherapy
Number of subjects: 0
Study 37709314 — intervention group
Group type: COMPARATOR
Intervention: nCRT
Number of subjects: 0
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA and preterm birth
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA and term/post-term birth
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate-for-gestational-age/large-for-gestational-age and preterm birth
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prior child deaths
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a twin or triplet
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Births at health posts/clinics or in hospital
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Births on the way to facilities or outdoors
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height <145 cm
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height 145-150 cm
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or more antenatal care visits
Number of subjects: 40119
Study 37709319 — intervention group
Group type: EXPERIMENTAL
Intervention: Education >5 years
Number of subjects: 40119
Study 37709320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sivelestat sodium for up to 7 days
Number of subjects: 238
Study 37709320 — intervention group
Group type: COMPARATOR
Intervention: Placebo for up to 7 days
Number of subjects: 238
Study 37709324 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-based digital health interventions for managing diabetes distress (DD)
Number of subjects: 20
Study 37709324 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires assessing socio-demographics, diabetes management, e-Health literacy, and diabetes distress
Number of subjects: 20
Study 37709327 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (telephone consultations)
Number of subjects: 125
Study 37709327 — intervention group
Group type: COMPARATOR
Intervention: In-person consultation
Number of subjects: 125
Study 37709336 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock climbers
Number of subjects: 0
Study 37709336 — intervention group
Group type: COMPARATOR
Intervention: Non-athlete control group
Number of subjects: 0
Study 37709337 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered meal replacement (PMR) group: replacing morning and afternoon snacks daily with a PMR for 12 weeks
Number of subjects: 88
Study 37709337 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON): maintaining usual diet for 12 weeks
Number of subjects: 88
Study 37709339 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to surgery after COVID-19 diagnosis
Number of subjects: 0
Study 37709338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 0
Study 37709338 — intervention group
Group type: COMPARATOR
Intervention: Non-CD control subjects
Number of subjects: 0
Study 37709527 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30 kg/m²)
Number of subjects: 431
Study 37709527 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients
Number of subjects: 431
Study 37709550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 60
Study 37709550 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 60
Study 37709661 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1015550 (9 mg or 18 mg)
Number of subjects: 0
Study 37709661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37709944 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacking frequency and quality (measured by snack diet index - SDI)
Number of subjects: 1002
Study 37709952 — intervention group
Group type: EXPERIMENTAL
Intervention: Height/weight-adjusted spinal bupivacaine
Number of subjects: 112
Study 37709952 — intervention group
Group type: COMPARATOR
Intervention: Height-adjusted spinal bupivacaine
Number of subjects: 112
Study 37709984 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPT + LLLT
Number of subjects: 0
Study 37709984 — intervention group
Group type: COMPARATOR
Intervention: NSPT (Sham)
Number of subjects: 0
Study 37709984 — intervention group
Group type: COMPARATOR
Intervention: Healthy (Control)
Number of subjects: 0
Study 37709999 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 104
Study 37709999 — intervention group
Group type: COMPARATOR
Intervention: Placebo with therapy
Number of subjects: 104
Study 37710000 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based reinforcement learning (RL-DITR)
Number of subjects: 16
Study 37710000 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical methods and other deep learning models
Number of subjects: 16
Study 37710001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab plus lazertinib
Number of subjects: 45
Study 37710005 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) as second-line therapy
Number of subjects: 62
Study 37710085 — intervention group
Group type: EXPERIMENTAL
Intervention: diluted thrombin time (dTT)
Number of subjects: 60
Study 37710085 — intervention group
Group type: EXPERIMENTAL
Intervention: ecarin-based chromogenic assay (ECA-II)
Number of subjects: 60
Study 37710085 — intervention group
Group type: COMPARATOR
Intervention: UPLC-MS (reference method)
Number of subjects: 60
Study 37710085 — intervention group
Group type: EXPERIMENTAL
Intervention: dTT and ECA-II assays
Number of subjects: 60
Study 37710178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based follow-up
Number of subjects: 1434
Study 37710178 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care service follow-up
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Achievement of blood pressure targets
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Achievement of LDL-cholesterol goals
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Achievement of HbA1c-goal in patients with diabetes
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking status
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Healthy diets
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Use of acetylsalicylic acid
Number of subjects: 1434
Study 37710178 — intervention group
Group type: COMPARATOR
Intervention: Use of lipid lowering therapy
Number of subjects: 1434
Study 37710194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasmart hybrid ceramic
Number of subjects: 102
Study 37710194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita Enamic polymer infiltrated ceramic network (PICN) crowns
Number of subjects: 102
Study 37710194 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 102
Study 37710198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day) for 5 years
Number of subjects: 810
Study 37710198 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) with conventional fractions (50 Gy in 25 fractions) or hypofractionations (40.05 Gy in 15 fractions)
Number of subjects: 810
Study 37710198 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and adverse effects of RT and tamoxifen
Number of subjects: 810
Study 37710269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated sliding hip screw (SHS)
Number of subjects: 37
Study 37710269 — intervention group
Group type: COMPARATOR
Intervention: Non-coated lag screw thread
Number of subjects: 37
Study 37710274 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 722
Study 37710274 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 722
Study 37710315 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-arachidonoyl-lysophatidylcholine (2-AA-LPC) in carotid plaques from T2DM patients
Number of subjects: 0
Study 37710315 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation markers (hsCRP, IL-1β)
Number of subjects: 0
Study 37710315 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxysterols, triglyceride levels, HDL levels
Number of subjects: 0
Study 37710315 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 2-AA-LPC with inflammatory markers within plaques
Number of subjects: 0
Study 37710376 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal protein intake (0.2 g·kg-1·d-1)
Number of subjects: 15
Study 37710376 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein intake (1.2 g·kg-1·d-1)
Number of subjects: 15
Study 37710376 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess protein intake (2.0 g·kg-1·d-1)
Number of subjects: 15
Study 37710376 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended protein intake for males (1.81 g·kg-1·d-1)
Number of subjects: 15
Study 37710376 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended protein intake for females (1.89 g·kg-1·d-1)
Number of subjects: 15
Study 37710376 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper 95% confidence interval protein intake (~1.85 g·kg-1·d-1)
Number of subjects: 15
Study 37711159 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life assessment
Number of subjects: 0
Study 37711159 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs assessment for caregivers
Number of subjects: 0
Study 37711193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation
Number of subjects: 50
Study 37711193 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging of the bladder
Number of subjects: 50
Study 37711193 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA clearance
Number of subjects: 50
Study 37711198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5ug), QID dosing
Number of subjects: 34
Study 37711219 — intervention group
Group type: EXPERIMENTAL
Intervention: GBP510/AS03
Number of subjects: 4036
Study 37711219 — intervention group
Group type: COMPARATOR
Intervention: ChAdOx1-S
Number of subjects: 4036
Study 37711623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with ITI-3000 (a cancer vaccine targeting MCPyV-LT)
Number of subjects: 0
Study 37711718 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of caffeine
Number of subjects: 10
Study 37711718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10